Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL45491 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL17760706 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20590930 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1684053 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20954938 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL9319654 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL21802305 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20994443 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL22558234 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL10477645 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101743012-A | The novel one step process for preparing crosslinked poly-(allylamine) polymer | CHEMO IBERICA SA | 2010-06-16 | — | — | CN | claimed |
| EP-2175866-A1 | NOVEL ONE STEP PROCESS FOR PREPARING CROSS-LINKED POLY(ALLYLAMINE) POLYMERS | Chemo Ibérica, S.A. (ES) | 2010-04-21 | — | — | EP | claimed |
| WO-2009010531-A1 | NOVEL ONE STEP PROCESS FOR PREPARING CROSS-LINKED POLY(ALLYLAMINE) POLYMERS | CHEMO IBÉRICA, S.A. (ES) | 2009-01-22 | — | — | WO | claimed |
| EP-2016947-A1 | Novel one step process for preparing cross-linked poly(allylamine) polymers | Chemo Ibérica, S.A. (ES) | 2009-01-21 | — | — | EP | claimed |
| EP-2614049-B1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics GmbH (AT) | 2018-02-28 | — | — | EP | disclosed |
| US-9278920-B2 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-03-08 | — | — | US | disclosed |
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2013-10-17 | — | — | US | disclosed |
| EP-2614049-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics AG (AT) | 2013-07-17 | — | — | EP | disclosed |
| US-8394416-B2 | One step process for preparing cross-linked poly(allylamine) polymers | CHEMO IBÉRICA, S.A. (ES) | 2013-03-12 | — | — | US | disclosed |
| CN-101743012-B | Novel one step process for preparing cross-linked poly(allylamine) polymers | CHEMO IBERICA SA | 2012-07-04 | — | — | CN | disclosed |
| EP-2433926-A1 | Pleuromutilin derivatives for use in the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (AT) | 2012-03-28 | — | — | EP | disclosed |
| WO-2012031307-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2012-03-15 | — | — | WO | disclosed |
| EP-2175866-B1 | NOVEL ONE STEP PROCESS FOR PREPARING CROSS-LINKED POLY(ALLYLAMINE) POLYMERS | CHEMO IBERICA SA (ES) | 2010-12-29 | — | — | EP | disclosed |
| US-20100183732-A1 | Novel one step process for preparing cross-linked poly(allylamine) polymers | CHEMO IBERICA, S.A. (ES) | 2010-07-22 | — | — | US | disclosed |
| CN-101743012-A | The novel one step process for preparing crosslinked poly-(allylamine) polymer | CHEMO IBERICA SA | 2010-06-16 | — | — | CN | disclosed |
| EP-2175866-A1 | NOVEL ONE STEP PROCESS FOR PREPARING CROSS-LINKED POLY(ALLYLAMINE) POLYMERS | Chemo Ibérica, S.A. (ES) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009010531-A1 | NOVEL ONE STEP PROCESS FOR PREPARING CROSS-LINKED POLY(ALLYLAMINE) POLYMERS | CHEMO IBÉRICA, S.A. (ES) | 2009-01-22 | — | — | WO | disclosed |
| EP-2016947-A1 | Novel one step process for preparing cross-linked poly(allylamine) polymers | Chemo Ibérica, S.A. (ES) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274329-A1 | PLEUROMUTILIN DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Q6ZSR9, CUTA, MC4R | MEN1 1688/4885ALDH1A1 435/4885HMGCR 795/4885 |
| US-20100183732-A1 | Novel one step process for preparing cross-linked poly(allylamine) polymers | MACF1, ALG1, LIG4 | MEN1 2999/4885ALDH1A1 204/4885HMGCR 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.